The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Open accessAbstract
Background: Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell lymphoma. Several case series have described opportunistic infections among ibrutinib recipients, but the full extent of these infections is unknown. We sought to determine the spectrum of serious infections associated with ibrutinib treatment. Methods: We reviewed the electronic medical records of patients with lymphoid cancer at Memorial Sloan Kettering Cancer Center who received ibrutinib during a 5-year period from 1 January 2012 to 31 December 2016. Serious infections were identified by review of the relevant microbiology, clinical laboratory, and radiology data. Risk factors for infection were determined by means of univariate and multivariate analyses. Results: We analyzed findings in 378 patients with lymphoid cancer who received ibrutinib. The most common underlying cancers were chronic lymphocytic leukemia and mantle cell lymphoma. 84% of patients received ibrutinib as monotherapy. Serious infection developed in 43 patients (11.4%), primarily during the first year of ibrutinib treatment. Invasive bacterial infections developed in 23 (53.5%) of these patients, and invasive fungal infections (IFIs) in 16 (37.2%) .The majority of patients with IFIs during ibrutinib therapy (62.5%) lacked classic clinical risk factors for fungal infection (ie, neutropenia, lymphopenia, and receipt of corticosteroids). Infection resulted in death in 6 of the 43 patients (14%). Conclusions: Patients with lymphoid cancer receiving ibrutinib treatment are at risk for serious infections, including IFIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, treatment of patients with lymphoproliferative malignancies with inhibitors of BTK has resulted in a surge in cases of invasive aspergillosis (79, 264).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [264]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Vetrie, D. L. P., Vořechovský, I., Sideras, P., Holland, J., Davies, A. F., Flinter, F. A., Hammarström, L. L. G., Kinnon, C., Levinsky, R. J., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,465
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I. J., Sparkes, R. S., Kubagawa, H., Mohandas, T. K., Quan, S. G., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,326
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 3×
“Ibrutinib was approved by the US Food and Drug Administration for the treatment of patients with CLL, previously treated mantle cell lymphoma (MCL) or marginal zone lymphoma, WM, or refractory chronic graft-versus-host disease, and by the European Medicines Agency for the treatment of patients with CLL, WM, or previou…”
MethodIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D. L., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 951
Self-citationByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 674
Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes
Thomas, J. D., Sideras, P., Smith, C. I. E., Vořechovský, I., Chapman, V. M., & Paul, W. E. (1993) · Science · doi:10.1126/science.8332900 · Cited by 613
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D. B., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 520
Research works printed but not linked: 1
- Smith, 1993–2018, X-linked agammaglobulinemia
Cited by
Sorted by citations
Items 201–271 of 271
Srisurapanont, K., Meejun, T., Manothummetha, K., Li, L. X., Baddley, J. W., Schulz, C. A., Dioverti, M. V., Zhang, S. X., Avery, R. K., Kates, O. S., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019221 · Cited by 2
Hansenne, A., Camboni, A., Neste, E. V. D., & Bailly, S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1964023 · Cited by 2
Benefits of early antifungal therapy in hematology patients
Andreev, S. S., Бронин, Г. О., Epifanova, N. Y., Kozlova, O. P., Пристанскова, Е. А., Khostelidi, S. N., & Витальевна, Ш. О. (2024) · Oncohematology · doi:10.17650/1818-8346-2024-19-1-99-112 · Cited by 2
Rezig, S., Talarmin, J., Gal, S. L., & Saad, H. (2025) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2025.101586 · Cited by 2
Vaccination in Patients with Chronic Lymphocytic Leukemia: Current Problems
Kislova, M. I., Petrenko, A. A., Костинов, М. П., & Nikitin, E. A. (2021) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2021-20-3-91-106 · Cited by 2
The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
Muttana, S., Singh, C. S., Kim, H., Smith, C. J., & Michael, M. B. (2021) · Cureus · doi:10.7759/cureus.20639 · Cited by 2
Yasu, T., Sakurai, K., & Akazawa, M. (2022) · Current Oncology · doi:10.3390/curroncol29050264 · Cited by 3
Aspergillosis: Beyond the oncohematological patient
Ruíz-Camps, I. (2019) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2019.10.002 · Cited by 2
Guo, Y., Aufiero, M. A., Mills, K. A. M., Grassmann, S. A., Kim, H., Zumbo, P., Gjonbalaj, M., Billips, A., Mar, K. B., Yu, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.24.620079 · Cited by 2
Self-citationCriscuolo, M., Fracchiolla, N., Farina, F., Verga, L., Pagano, L., & Busca, A. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2290639 · Cited by 1
Ibrutinib and Neurolisteriosis: Simple Coincidence?
Dalmas, P., Mortier, C., Froidefond, M., Doudier, B., Dudouet, P., Collignon, A., Ebbo, M., Lagier, J., & Cassir, N. (2024) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2023.1280 · Cited by 1
Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies
Goede, J. S., Baumann, C. K., Cathomas, R. L., Khanna, N., Lambert, J., Lehmann, T., Mey, U., Seebach, J. D., Steiner, U. C., Tschan‐Plessl, A., et al. (2024) · Swiss Medical Weekly · doi:10.57187/s.3559 · Cited by 1
Williams, L. J., Suen, C. S. N. L. W., Garnham, A. L., Bader, S. M., Tam, C. S. L., Whitechurch, A., Slavin, M. A., Doerflinger, M., & Teh, B. W. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70049 · Cited by 1
Guo, Y., Aufiero, M. A., Mills, K. A. M., Grassmann, S. A., Kim, H., Gjonbalaj, M., Zumbo, P., Billips, A., Mar, K. B., Yu, Y., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci190107 · Cited by 3
Self-citationSecondary antibody deficiencies: what’s around the corner?
Lagnese, G., Messuri, C., Poto, R., Varricchi, G., & Spadaro, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1672413 · Cited by 1
Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls
Spanberger, T. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0466-1 · Cited by 1
Rodriguez, R. R., Alhamad, K., Ghosh, S., Bihler, E., & Raj, M. S. (2021) · Cureus · doi:10.7759/cureus.20574 · Cited by 1
Bretagne, S., & Климко, Н. Н. (2020) · Hematologic malignancies · doi:10.1007/978-3-030-57317-1_8 · Cited by 1
Neurologic complications of oncologic therapy
Budhu, J. A., Wen, P. Y., & Lee, E. Q. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822835-7.00013-5 · Cited by 1
Cryptococcal Pneumonia in a Patient on Tyrosine Kinase Inhibitor Therapy: How Common Is It?
Sung, D., Singh, S., & Goswami, S. K. (2023) · Cureus · doi:10.7759/cureus.47884 · Cited by 1
Yadav, Y., Montano, F. C., Plocharczyk, E. F., MacQueen, D., & Gupta, S. (2025) · Cureus · doi:10.7759/cureus.81113 · Cited by 1
Crook, P., Grey‐Davies, E., Khan, F., & Bicanic, T. A. (2025) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2025.100505 · Cited by 1
Aguilar, C., Serris, A., Paccoud, O., Jullien, V., Alanio, A., Frange, P., Lanternier, F., & Lortholary, O. (2026) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/s1166-8598(25)45573-2 · Cited by 1
Invasive Mold Infections in Patients with Chronic Lymphoproliferative Disorders
Facchinelli, D., Marchesini, G., Nadali, G., & Pagano, L. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0327-8 · Cited by 1
Autore, F., Innocenti, I., Morelli, F., Sorà, F., Corbingi, A., Fianchi, L., Criscuolo, M., Pagano, L., Sica, S., & Laurenti, L. (2019) · Hematological Oncology · doi:10.1002/hon.2623 · Cited by 1
Malignancies in immune deficiencies
Khalil, M., Przespolewski, A., & Segal, B. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816768-7.00051-x · Cited by 1
Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates
Saling, C. F., Feller, F. F., & Vikram, H. R. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-237085 · Cited by 1
Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report
Li, Q., Liu, W., Li, K., Tian, Y., & Li, H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s300805 · Cited by 1
A Woman with Relapsed Chronic Lymphocytic Leukemia and Upper Lobe Consolidation
Paccoud, O., Barnier, J., Lanternier, F., & Lortholary, O. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202012-1538cc · Cited by 1
Invasive Aspergillosis of the Spleen in the setting of Ibrutinib use
Asawa, P., Chahine, Z., Vusqa, U. T., Samhouri, Y., & Fazal, S. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221077641 · Cited by 1
Immunosuppressive agents and monitoring in long‐term survivors
Culos, K. A. A., & Gatwood, K. S. (2021) · Wiley eBooks · doi:10.1002/9781119612780.ch37 · Cited by 1
Epidemiology of Infections Caused by Molds
Cuellar‐Rodríguez, J., & Ostrosky-Zeichner, L. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21006-6 · Cited by 1
Eades, C. P., & Bapat, A. (2019) · British Journal of Haematology · doi:10.1111/bjh.15929
Wilson, W. H., Staudt, L. M., & Younes, A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01603
Infectious Complications of Biological Agents
Fong, I. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-36966-8_6
Fungal Infections in the Setting of Biological Therapies (in the Non-Transplant Host)
Lionakis, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21022-4
HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
Wallace, M. R. (2020) · Case Reports in Infectious Diseases · doi:10.1155/2020/6516037
Invasive Fungal Infection Complicating Treatment With Ibrutinib
Rajapakse, P., Gupta, M., & Hall, R. (2021) · Cureus · doi:10.7759/cureus.16009
Treatment of Secondary Immunodeficiencies
Schweitzer, L., Korsos, V., & Vinh, D. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00175-0
Mucormycosis in a Patient with Chronic Lymphatic Leukemia in Treatment with Ibrutinib
Fodstad, P., Lein, I. A., & Tjønnfjord, G. E. (2021) · Journal of Bacteriology and Mycology · doi:10.26420/jbacteriolmycol.2021.1184
Librarianship education, employability and equality
Chelin, J. A. (2007) · UWE Research Repository (UWE Bristol)
Şahin, U., Soydan, E., Urlu, S. M., Okcu, M. K., Ozkumur, K. O., Şen, Ş., & Gökmen, A. (2022) · LLM Dergi · doi:10.5578/llm.20229904
Duarte, R. F., Sánchez‐Ortega, I., & Sheppard, D. C. (2020) · Hematologic malignancies · doi:10.1007/978-3-030-57317-1_3
Aspergillosis: Beyond the oncohematological patient
Ruíz-Camps, I. (2020) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2019.10.001
(2018) · Reactions Weekly · doi:10.1007/s40278-018-55232-3
CNS-invasive aspergillosis following ibrutinib therapy
Kurian, M., Eric, V., & Khanapara, D. B. (2022) · International Journal of Immunotherapy and Cancer Research · doi:10.17352/2455-8591.000035
Paige, E. K., Abbinga, S. J., & Slavin, M. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-11363-5_21
Gkrania‐Klotsas, E. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14124
Proteoform-level deconvolution reveals a broader spectrum of ibrutinib off-targetsPreprint
Leo, I. R., Kunold, E., Audrey, A., Tampere, M., Eirich, J., & Jafari, R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.14.566837
Diffüz Büyük B Hücreli Lenfomada İbrutinib Etkinliğinin Değerlendirilmesi: Tek Merkez Deneyimi
Uysal, A., & Merter, M. (2023) · LLM Dergi · doi:10.5578/llm.20239904
Hamada, A., Yamaguchi, K., Kitadai, E., Sakamoto, S., Horimasu, Y., Masuda, T., Nakashima, T., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2024) · Respiratory Endoscopy · doi:10.58585/respend.2023-0045
Complications infectieuses des nouvelles immunothérapies et thérapies ciblées
Brunel, A.-S., & Ader, F. (2024) · Médecine et Maladies Infectieuses Formation · doi:10.1016/j.mmifmc.2024.09.007
Medina, Á., Muntañola, A., Crespo, M., Ramírez, Á., Hernández‐Rivas, J., Abrisqueta, P., Alcoceba, M., Delgado, J., de la Serna, J., Espinet, B., et al. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.10.012
Hairy cell leukemia, Legionella and ibrutinib: Old friends and a new foe
Marco, D. N., Castiaux, J., Fernández, S., & Mariotte, É. (2025) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2025.06.015
Mucorales Endocarditis: A Case Series and Review of the Literature
Elattar, S., Ghosh, K., Tatem, L. L., Rojas-Marte, G. R., Pastorino, T., Eapen, J., & Khoury, M. Y. E. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001026
Considerations for the treatment of older adults with chronic lymphocytic leukemia
Pula, A. E., & Robak, T. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2566834
Hairy cell leukemia, Legionella and ibrutinib: Old friends and a new foe
Marco, D. N., Castiaux, J., Fernández, S., & Mariotte, É. (2025) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2025.06.010
Yan, Q., Guo, L., & Sun, Q. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682758
CALVO, R. B., González-Resina, R., Rubio‐Martínez, A., Leciñena, I. L., Delgado-Beltrán, M. P., & Sazatornil, M. R. A. (2026) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.11.012
Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?
Šimkovič, M., Vejražková, E., Écsiová, D., & Vodárek, P. (2025) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2026.1
CALVO, R. B., González-Resina, R., Rubio‐Martínez, A., Leciñena, I. L., Delgado-Beltrán, M. P., & Sazatornil, M. R. A. (2026) · Farmacia Hospitalaria · doi:10.1016/j.farma.2026.03.010
Andreescu, M., Tudorache, S. I., Moldovan, C., Moldovan, A.-D., Cochior, D., Popov, V., Andreescu, B., Ionescu, D., & Padurariu-Covit, M.-D. (2026) · Cancers · doi:10.3390/cancers18101621
Singh, M., Podder, D., Jacoby, A. P., Saha, S., Chatterji, S. N., Ghosh, S., Chattopadhyay, D., Kumar, J., Nag, A., Javed, R., et al. (2026) · Cureus · doi:10.7759/cureus.110182
Safety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia
Ailawadhi, S., Omercikoglu, E., Paulus, A., Parrondo, R. D., & Chanan-Khan, A. A. (2026) · Drug Safety · doi:10.1007/s40264-026-01678-2
Persico, M., Haston, J. C., Imada, E., Kasten, J., Pimentel, C., & Collins, J. M. (2026) · Emerging infectious diseases · doi:10.3201/eid3209.260790
Arias‐Hidalgo, C., H-Vázquez, J., Teodósio, C., Juanes‐Velasco, P., Nuño-Soriano, A., Cal‐Sabater, P., Arribas‐Rodríguez, E., Fiz‐López, A., Mazzali, M. P., Martín‐Muñoz, Á., et al. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00394
Infections chez le patient immunodéprimé en réanimation
Mokart, D., Bisbal, M., Gonzalez, F., Chow‐Chine, L., Faucher, M., & Roger, C. (2026) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(26)49706-6
Shukla, A., Pandey, A., Verma, S. K., Sinha, S., Tripathi, A., Shukla, N., Dutta, G., & Raghuveer, P. (2026) · Cureus · doi:10.7759/cureus.117629
Sarıcı, A. M., Kaya, E., Kuku, İ., Erkurt, M. A., Berber, İ., Javanmard, S., Memişoğlu, F., Tanrıverdi, E. S., Berktas, M. B., & Otlu, B. (2026) · Pharmaceuticals · doi:10.3390/ph19111694
Tsai, Y., Lin, H.-C., Yang, W., Lin, T., & Tsai, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1979881
Metadata
- Authors
- Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Infectious Diseases Service, Memorial Sloan Kettering Cancer Center
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-27
- Volume
- 67
- Issue
- 5
- Pages
- 687-692
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6093991
- OpenAlex
- W2789508123
- Cited by
- 271
- References
- 36
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 25 · 2022: 26 · 2021: 50 · 2020: 56 · 2019: 36 · 2018: 15
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30 CA008748)
- National Institutes of Health (K08 CA184038)
- Topics
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- ibrutinib, serious infections, lymphoid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, BTK inhibitors, invasive fungal infections, invasive bacterial infection, infection risk factors, opportunistic infections
- MeSH terms
- Invasive Fungal Infections, Adenine, Adult, Aged, Aged, 80 and over, Bacterial Infections, Female, Humans, Lymphopenia, Male, Middle Aged, New York, Opportunistic Infections, Piperidines, Pyrazoles, Pyrimidines, Risk Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Young Adult, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
